Eiger BioPharmaceuticals falls after CEO steps down
16/12/2022 17:36
** Shares of therapy developer Eiger BioPharmaceuticals Inc
EIGR.O drop 9.3% to $1.17
** Company says David Cory has resigned as CEO, effective
immediately urn:newsml:reuters.com:*:nBw3sJ8VGa
** Eiger names its Senior Clinical Advisor David Apelian as
interim CEO
** Shares of company plunged last week after it reported two
deaths in an end-stage study of its medication for Hepatitis
Delta Virus
** Including session's loss, stock down 77.6% YTD
(Reporting by Sourasis Bose in Bengaluru)
((Sourasis.bose@thomsonreuters.com))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview